Syngene International Ltd

Q4 FY26Healthcare Services

Syngene International Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹407

Market cap₹16.4K Cr

P/E55.5

Updated23 Aug 2026

Read5 min read

What the Q4 FY26 call signalled

1 of 3 strong

RevenueRank 4

MarginRank 3

CapexYes

Not discussed on this call: fundraise, order book.

The short version

FY27 guidance expects broadly flat revenue performance compared to FY26, with growth weighted towards the second half of the year as new contracts ramp up. FY27 is expected to have broadly flat revenue growth with EBITDA margins maintained in the mid-20s % through disciplined cost management.

From Syngene International Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Rank 4

FY27 guidance expects broadly flat revenue performance compared to FY26, with growth weighted towards the second half of the year as new contracts ramp up.
The adverse impact of Librela destocking is expected to continue through H1 FY27, with near-zero Librela volumes anticipated in the first two quarters and only minor volumes thereafter.
Post FY27, Syngene expects to reset its baseline and enter a phase of sustainable and higher growth, driven by pipeline maturation and investments in new modalities like peptides, ADCs, and biologics.
The company anticipates stronger growth from FY28 onwards as the Librela effect washes out and new capabilities begin to deliver.
Syngene is focusing on expanding its CDMO business, which is expected to contribute more aggressive and sustainable growth.
Overall, management guides for single-digit underlying growth excluding Librela impact and aims to capitalize on emerging opportunities for volume and revenue expansion.

Profitability & Margins

FY27 is expected to have broadly flat revenue growth with EBITDA margins maintained in the mid-20s % through disciplined cost management.
H1 FY27 will be muted due to ongoing impact from Librela destocking; H2 FY27 is expected to be meaningfully stronger with new contracts ramping up.
FY27 represents a year of strategic reset; a healthy pipeline of deal flow is expected to translate into stronger growth from FY28 onwards.
Growth beyond FY27 is anticipated from maturation of pipelines, new capabilities in peptides, ADCs, biologics, and AI-enabled services.
Margin improvement is expected over time as utilization of new sites improves, targeting aspirationally high 20%-30%, though guidance remains mid-20% for FY27.
The business aims to achieve more aggressive and sustainable growth primarily through expansion in the CDMO segment.
Overall, Syngene positions for sustained earnings and profit growth starting FY28 after the transitional period in FY27.

See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Syngene continues to invest in building capabilities and technologies to become an integrated solution provider.
In Q4 FY26, invested $10 million focused 50% on research services (capability build, contractual obligations, dedicated centers, and maintenance).
About 40% of capex was directed to the CDMO business.
The remaining capex was toward digitization, automation, and common infrastructure.
Commissioned a new commercial scale facility for liquid-filled hard gelatin capsules, enhancing oral solid dosage capabilities.
Expanded Bengaluru biologics facility with a GMP bioconjugation suite for end-to-end antibody drug conjugates manufacturing.
Bayview biologics facility in the U.S. is progressing toward operationalization in FY27 with ongoing investments and trial runs.
Capex timelines for Bayview still being updated; expected to continue impacting margins in FY27.
Investments target new modalities like peptides and ADCs aligning with growth and long-term strategic positioning.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The transcript does not mention any plans for new fundraising through debt or equity in the current or near future.
The company highlights maintaining a strong balance sheet with a net cash balance of INR1,800 crores as of March 31, 2026.
Interest expense declined by 24% in Q4 FY26 due to reduced borrowing, indicating manageable debt levels.
Capex is being funded internally, with $10 million invested in Q4 FY26 across research, CDMO, and automation.
No specific comments were made by management regarding plans or intentions to raise additional capital via debt or equity.
The focus is on disciplined cost management, operational execution, and strategic investments rather than external fundraising.

See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly provide specific figures or detailed information on Syngene's current or expected orderbook/pending orders.
However, it mentions a "healthy pipeline of deal flows" expected to translate into stronger growth from FY28 onwards.
Syngene is seeing encouraging interest and increased client interactions at their biologics facilities (Bayview and Unit 3), indicating a growing order pipeline.
The extended long-term collaboration with Bristol-Myers Squibb through 2035 suggests a stable and strategic order flow over the next decade.
The company is actively engaging with prospective customers as the Bayview biologics facility in the U.S. moves toward operationalization, which supports future order growth.
Overall, the outlook points to a growing and healthy order pipeline, especially from FY28, but no specific orderbook numbers are disclosed.

Syngene International Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹148 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Syngene International Ltd's management said in earlier quarters

Others in Healthcare Services this season

Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
Health X Platform Ltd (Q4 FY26)
Northeast operations growing 50%+ year-on-year and Northern India 25–30%, with plans for 5–7% market share in 2-3 years (Page 10). Key concall takeaways from…
Park Medi World Ltd (Q4 FY26)
Total planned capex for the next two years is around INR 500 crores. Key concall takeaways from Park Medi World's Q4 FY26 earnings call — and how it ranks…
Vimta Labs Ltd (Q4 FY26)
. Key concall takeaways from Vimta Labs Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare Institute Ltd vs Manipal Health Enterprises Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Syngene International Ltd Q4 FY26 results?

What is Syngene International Ltd share price analysis?

Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.

Is Syngene International Ltd planning capital expenditure?

Syngene continues to invest in building capabilities and technologies to become an integrated solution provider. - In Q4 FY26, invested $10 million focused 50% on research services (capability build, contractual obligations, dedicated centers, and maintenance). - About 40% of capex was directed to the CDMO business. - The remaining capex was toward digitization, automation, and common infrastructure. - Commissioned a new commercial scale facility for liquid-filled hard gelatin capsules, enhancing oral solid dosage capabilities. - Expanded Bengaluru biologics facility with a GMP bioconjugation suite for end-to-end antibody drug conjugates manufacturing. - Bayview biologics facility in the U.S.

Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.